Buy Raloxifene from Canada

$141.00

Raloxifene selectively binds to estrogen receptors in the body, exhibiting estrogenic and anti-estrogenic activities depending on the target tissues. In bones, it maintains bone density and reduces bone turnover, helping to mitigate the risk of fractures—a significant concern post-menopause. Conversely, it counteracts the effects of estrogen on the breast and uterine tissues, thus presenting a protective effect against certain forms of cancer associated with high estrogen levels. This distinctive dual action makes raloxifene a cornerstone drug for many women navigating the postmenopausal period.

- +
Compare
Category:

Description

Raloxifene, marketed under the brand name Evista among others, is a selective estrogen receptor modulator (SERM) renowned for its efficacy in treating and preventing osteoporosis in postmenopausal women. It also plays a pivotal role in reducing the risk of invasive breast cancer in postmenopausal women who are at high risk or have osteoporosis. By mimicking the bone-protective effects of estrogen without its potentially adverse impact on the breast and uterus, raloxifene represents a finely-tuned intervention in hormonal therapy.